Open AccessCost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico
Author(s) -
JaimePérez José Carlos,
HerediaSalazar Alberto Carlos,
CantúRodríguez Olga G.,
GutiérrezAguirre Homero,
VillarrealVillarreal César Daniel,
MancíasGuerra Consuelo,
HerreraGarza José Luís,
GómezAlmaguer David
Publication year - 2015
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2014-0218
Subject(s) - medicine , hematopoietic stem cell transplantation , transplantation , acute myeloblastic leukemia , pediatrics , leukemia , surgery , intensive care medicine
Background and Objective. Hematopoietic stem cell transplantation (HSCT) in developing countries is cost‐limited. Our primary goal was to determine the cost structure for the HSCT program model developed over the last decade at our public university hospital and to assess its clinical outcomes. Materials and Methods. Adults and children receiving an allogeneic hematopoietic stem cell transplant from January 2010 to February 2011 at our hematology regional reference center were included. Laboratory tests, medical procedures, chemotherapy drugs, other drugs, and hospitalization costs were scrutinized to calculate the total cost for each patient and the median cost for the procedure. Data regarding clinical evolution were incorporated into the analysis. Physician fees are not charged at the institution and therefore were not included. Results. Fifty patients were evaluated over a 1‐year period. The total estimated cost for an allogeneic HSCT was $12,504. The two most expensive diseases to allograft were non‐Hodgkin lymphoma ($11,760 ± $2,236) for the malignant group and thalassemia ($12,915 ± $5,170) for the nonmalignant group. Acute lymphoblastic leukemia ($11,053 ± 2,817) and acute myeloblastic leukemia ($10,251 ± $1,538) were the most frequent indications for HSCT, with 11 cases each. Median out‐of‐pocket expenses were $1,605, and 1‐year follow‐up costs amounted to $1,640, adding up to a total cost of $15,749 for the first year. The most expensive components were drugs and laboratory tests. Conclusion. Applying the cost structure described, HSCT is an affordable option for hematological patients living in a developing country.